Immune Thrombocytopenic Purpura (ITP) Market
Key Highlights
The Immune Thrombocytopenic Purpura market is entering a transformative phase, shaped by an evolving therapeutic landscape, a robust pipeline of emerging treatments, and a growing understanding of disease mechanisms. The total market size across the 7 Major Markets (7MM) for ITP was estimated at nearly USD 3,800 million in 2024, and is expected to grow at a significant CAGR during the forecast period through 2034.
- The United States dominated the 7MM, accounting for approximately 66% of the total ITP market share in 2024, underscoring the country’s advanced healthcare infrastructure and early adoption of novel therapies.
- In 2024, the total cases of ITP in the 7MM were approximately 186,000 cases, a figure expected to increase by 2034.
- Among EU4 and the UK, Germany recorded the highest number of ITP cases at around 19,000 in 2024, while Spain accounted for the fewest.
- ITP is more prevalent in females and is more commonly diagnosed in adults than in children.
- NPLATE and PROMACTA were both approved in 2008 as the first thrombopoietin receptor agonists (TPO-RAs) for treating chronic ITP, offering new options by directly stimulating platelet production.
Immune Thrombocytopenic Purpura Overview
Immune Thrombocytopenic Purpura (ITP) is an acquired immune-mediated disorder characterized by isolated thrombocytopenia and the absence of other identifiable conditions or agents known to cause low platelet counts. With an incidence of approximately 100 cases per 1 million persons annually, ITP presents across all age groups, though nearly 50% of cases occur in children, where the condition often resolves spontaneously.
ITP is defined as a decrease in platelet count due to immune processes. Primary ITP, with no underlying condition, accounts for 80% of cases, while Secondary ITP, linked to factors such as Systemic Lupus Erythematosus (SLE), drugs, Hepatitis C, HIV, Helicobacter pylori, and chronic lymphocytic leukemia, makes up the remaining 20%.
The disease may be acute or chronic. Acute ITP most commonly affects children between 2 and 6 years and may resolve within weeks to 6 months, often following a viral infection. Chronic ITP, by contrast, persists for at least 6 months, most frequently affects adult women, and requires continuous medical monitoring due to its recurrent nature.
The risk of bleeding correlates directly with the severity of thrombocytopenia. Clinical presentations range from asymptomatic discovery on routine bloodwork to life-threatening hemorrhage involving mucosal, intracranial, gastrointestinal, or genitourinary sites. Older patients and those on antiplatelet therapy face higher risks of severe bleeding manifestations.
Current guidelines recommend initiating treatment for platelet counts below 20–30 × 10⁹/L regardless of bleeding. For counts between 20–30 × 10⁹/L and 50 × 10⁹/L, treatment is generally not advised unless specific situations such as bleeding, surgery, or the need for antiplatelet or anticoagulant therapy arise.
Immune Thrombocytopenic Purpura Diagnosis
A careful history, physical examination, complete blood count (CBC), and review of the blood smear form the basis for a presumptive ITP diagnosis. Response to initial treatment with corticosteroids, intravenous immunoglobulin (IVIg), or anti-RhD supports the diagnosis and confirms the immune nature of thrombocytopenia.
Blood smear inspection confirms true platelet reduction and rules out platelet clumping or morphological abnormalities. Normal red and white blood cell counts help exclude leukemia and aplastic anemia, among other causes. Where unusual blood cell findings are present, bone marrow biopsy may be warranted to exclude secondary ITP or impaired platelet production.
Immune Thrombocytopenic Purpura Treatment
For many years, immune-modulating therapies such as corticosteroids, immunoglobulins (IVIg), splenectomy, and rituximab were the mainstays of ITP treatment. Splenectomy remains the only treatment that reliably provides long-term remission, with many patients achieving a year or more without further therapy. It remains a viable option for adults with ITP resistant to multiple treatments. A recent French study demonstrated a 46% sustained response rate in patients who failed TPO-RAs and rituximab, a rate slightly lower than historical benchmarks from before the introduction of agonists.
Current treatment options for ITP now include:
- Thrombopoietin Receptor Agonists (TPO-RAs): PROMACTA (eltrombopag), NPLATE (romiplostim), and DOPTELET (avatrombopag)
- Anti-CD20 Antibodies: RITUXAN (rituximab)
- Syk Inhibitors: TAVALISSE/TAVLESSE (fostamatinib)
- Neonatal Fc Receptor Inhibitors: VYVGART (efgartigimod)
- Various immunomodulatory agents
VYVGART, approved in Japan for adults with primary ITP, is poised to outperform competitors by delivering a superior sustained platelet response and maintaining a consistent safety profile, as demonstrated in the pivotal Phase III ADVANCE-IV trial.
Immune Thrombocytopenic Purpura Epidemiology
The Immune Thrombocytopenic Purpura market research epidemiology chapter provides historical and forecasted data segmented by total prevalent cases, age-specific diagnosed prevalence, and gender-specific diagnosed prevalence across the 7MM – covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
Among the 7MM, the United States accounts for the highest prevalent cases of ITP compared to the EU4, the UK, and Japan. ITP is more prevalent in females, with a notably higher prevalence compared to males. Patients with ITP are typically diagnosed as adults rather than children.
Immune Thrombocytopenic Purpura Marketed Drugs
- TAVALISSE/TAVLESSE (fostamatinib disodium hexahydrate) – Rigel Pharmaceuticals, Kissei Pharmaceutical, and Grifols
TAVALISSE is an orally bioavailable agent approved for treating patients with persistent or chronic adult ITP. It inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis. The drug has a unique mechanism of action, blocking IgG receptor signaling in both macrophages and B-cells via SYK kinase. TAVALISSE was approved by the US FDA in April 2018, gained European approval in January 2020, launched in Germany and the UK by July 2020, and received MHLW approval in Japan in December 2022, with its market launch in April 2023.
- DOPTELET (avatrombopag) – Sobi (Dova Pharmaceuticals) and Asahi Kasei Pharma
DOPTELET is an orally administered TPO-RA that mimics thrombopoietin’s biological effects, stimulating megakaryocyte development and maturation to increase platelet counts. It received FDA approval in June 2019 and EMA approval in January 2021 for treating chronic ITP in adults unresponsive to other therapies. In Q2 2024, Sobi announced plans for regulatory submission in Japan and pediatric submissions in the US and EU in the second half of 2024.
Immune Thrombocytopenic Purpura Emerging Drugs
The Immune Thrombocytopenic Purpura market insight is increasingly being shaped by a rich pipeline of next-generation therapies targeting novel mechanisms. The emergence of new therapeutic classes – including BTK inhibitors, anti-CD38 antibodies, CXCR5 antagonists, and BAFF/APRIL antagonists – is showing strong potential to redefine the standard of care.
- Rilzabrutinib (PRN-1008) – Sanofi/Principia Biopharma
Rilzabrutinib is an orally administered reversible covalent BTK inhibitor currently in Phase III development for adults and adolescents with persistent or chronic ITP. In April 2024, the company announced positive results from the LUNA 3 Phase III study, demonstrating that Rilzabrutinib 400 mg twice daily achieved the primary endpoint of durable platelet response. Rilzabrutinib is currently under regulatory review in the US, EU, and China. The target FDA action date for ITP, which has been granted fast track designation, is August 29, 2025.
- VAY736 (Ianalumab) – Novartis
Ianalumab is a novel, fully human IgG1 monoclonal antibody targeting the BAFF receptor with a unique dual mechanism: direct ADCC-mediated B-cell depletion and inhibition of B-cell differentiation, proliferation, and survival via BAFF-R signaling blockade. Currently in Phase III for both 1st and 2nd line ITP treatment, Novartis projected the upcoming results of the VAYHIT1 trial (first-line, expected 2026) and VAYHIT2 trial (anticipated 2025). The company anticipates submission of ianalumab in 1st and 2nd line ITP in 2027. Given that BAFF regulates B-cell differentiation and survival through BAFF-R, and autoreactive B cells play a key role in ITP, targeting BAFF-R presents a compelling and disease-modifying therapeutic approach.
Additional potential therapies that may mark a significant change during the forecast period include:
- Mezagitamab (Takeda)
- PF-06835375 (Pfizer)
- Cevidoplenib (Genosco/Oscotec)
All are being evaluated in advanced stages of clinical development.
Immune Thrombocytopenic Purpura Key Companies
The competitive landscape of the ITP market comprises a dynamic mix of established pharmaceutical leaders and innovative specialty players, including:
- Rigel Pharmaceuticals, Kissei Pharmaceutical, and Grifols
- Sobi (Dova Pharmaceuticals) and Asahi Kasei Pharma
- Amgen
- Argenx
- Grifols (Biotest)
- Zenyaku Kogyo and Chugai Pharmaceutical
- Novartis
- Sanofi/Principia Biopharma
- Takeda (Millennium Pharmaceuticals)
- Pfizer
- Genosco and Oscotec
- Roche/Chugai Pharmaceutical, and others
Conclusion
The Immune Thrombocytopenic Purpura market stands at a pivotal juncture. With a well-established base of TPO-RAs and immunomodulatory agents, and a pipeline brimming with breakthrough therapies, the landscape is set for meaningful transformation over the next decade. There is a strong and growing demand for disease-modifying therapies in ITP that offer sustained responses post-treatment – a gap that next-generation agents like ianalumab, rilzabrutinib, mezagitamab, and cevidoplenib are actively working to fill.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
